Northwire Canada EditionFriday, October 16, 2026
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

Telo Genomics increases private placement to $1.6M

TELO · Price

Executive Summary

  • Telo Genomics Corp. has upsized its previously announced non-brokered private placement of non-transferable secured convertible debentures from a maximum of $1.2 million to $1.6 million.
  • The company has already closed an initial tranche raising $840,000 and intends to close one or two additional tranches for up to $760,000, with the final tranche expected to close by March 6, 2026.
  • The offering consists of debentures bearing 15% annual interest, convertible into common shares at $0.05 per share, accompanied by detachable warrants exercisable at $0.08 per share.

Key Details

  • Offering Structure: Non-brokered private placement of non-transferable secured convertible debentures.
  • Upsized Amount: Increased from up to $1.2 million to up to $1.6 million.
  • Interest Rate: 15% per annum, compounded quarterly.
  • Maturity Date: December 15, 2026.
  • Conversion Terms: Holders may elect to convert principal into common shares at a conversion price of $0.05 per share at any time before maturity. The company has no right to prepay prior to maturity.
  • Warrant Terms: For every $100,000 of debentures issued, the company issues 2,000,000 detachable warrants. Each warrant is exercisable for one common share at an exercise price of $0.08 per share for a period of 12 months from the closing date.
  • Initial Tranche Closed: Aggregate gross proceeds of $840,000, consisting of debentures and 16.8 million warrants.
  • Remaining Tranches: Intends to close one or two additional tranches for aggregate gross proceeds of up to $760,000.
  • Closing Schedule: Final tranche expected to close on or before March 6, 2026.
  • Use of Proceeds: Working capital and general corporate purposes.
  • Regulatory Status: Subject to receipt of necessary regulatory approvals, including TSX Venture Exchange approval.
  • Hold Period: All securities subject to a statutory hold period of four months and one day from issuance.
  • Fees: The company may pay finders' fees in connection with the upsized offering.
Read the original news release →

More from Telo Genomics Corp